A new blood test developed by researchers at the University of Cambridge could revolutionize the diagnosis of mental illnesses, particularly schizophrenia and depression. Currently, diagnoses rely heavily on subjective conversations and questionnaires, leading to delayed and sometimes inaccurate assessments.
The innovative blood test, which examines specific proteins in blood samples, has shown remarkable accuracy, diagnosing schizophrenia with 83% certainty and depression with about 90% certainty. By providing objective biological markers, the test not only aids in diagnosis but also reduces the stigma associated with mental illness.
For individuals like Kirsty Trigg, who battled undiagnosed schizophrenia for over a decade, the test represents a beacon of hope. With early diagnosis and appropriate treatment, Kirsty’s life has transformed, enabling her to work and manage her condition effectively.
The blood test offers a significant advancement in understanding and addressing psychiatric disorders. Since the research commenced in 2008, scientists have persistently enhanced the tests. Furthermore, they’ve broadened their research to encompass tests for additional mental illnesses like anxiety. The resulting tests hold promise for personalized medication and improved treatment response rates, ushering in a new era of mental health care.
The Schizticks project was completed in 2012.
3:03
1920x1080
Video
